CML is a type of cancer that affects the bone marrow and blood. It is caused by a genetic abnormality that produces an abnormal protein called BCR-ABL. The development of new drugs that specifically target this protein has revolutionized the treatment of CML, but early diagnosis is still crucial for successful treatment outcomes.
The biosensor developed by Foregene uses a molecular beacon, which is a synthetic oligonucleotide that fluoresces when it binds to a complementary nucleic acid sequence. The biosensor can detect the BCR-ABL fusion gene, which is present in over 95% of CML cases, as well as the PCR amplification products of the gene.
The biosensor has several advantages over traditional detection methods. It is highly specific, as it only detects the BCR-ABL fusion gene and not other similar genes. It is also highly sensitive, detecting as few as 10 copies of the gene fragment or PCR product. The biosensor is also fast, taking only 30 minutes to complete the detection process.
Moreover, the biosensor is compatible with Foregene's Direct PCR platform, which allows for amplification of DNA directly from tissue samples without the need for DNA extraction. This simplifies the detection process and reduces the risk of contamination.
Foregene's biosensor has the potential to improve the accuracy and speed of CML diagnosis, which can lead to earlier and more effective treatment. The biosensor can also be used in research settings to study the molecular mechanisms of CML and to develop new drug targets.
Foregene's molecular beacon-based fluorescence biosensor is a promising development in the field of molecular diagnostics. It combines the specificity and sensitivity of molecular beacons with Foregene's advanced molecular biology platforms to create a powerful tool for the detection of CML-related gene fragments and PCR amplification products.